Martin H. Schuler, MD, on Gastric and GEJ Adenocarcinoma: Results of the FAST Study (German Language Version) 
2016 ESMO Congress
Martin H. Schuler, MD, of the University Hospital Essen, discusses in German findings from this phase II trial of epirubicin, oxaliplatin, and capecitabine with or without the antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ disease. (Abstract 614O)
Martin Reck, MD, PhD, of the LungenClinic, discusses study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)
Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)
Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)
Katja Weisel, MD, of the University of Tübingen, discusses study findings on daratumumab, bortezomib, and dexamethasone vs bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract 906O)
Tony Mok, MD, of The Chinese University of Hong Kong, discusses the final overall survival analysis from this trial on gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive non-small cell lung cancer after progression on first-line gefitinib. (Abstr 1201O)